NERVGEN PHARMA CORP.
Research NERVGEN PHARMA CORP. (9UA) on Bullrun: market cap EUR 198.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker9UA
- ExchangeF
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 198.60M
- Financial periodQ4 2025
- Net income-EUR 26.91M
- Free cash flow-EUR 6.40M
Valuation Snapshot
latest market cap is EUR 198.60M.
About NERVGEN PHARMA CORP.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease;
Frequently asked questions
What is NERVGEN PHARMA CORP.'s market cap?
NERVGEN PHARMA CORP.'s market capitalization is EUR 198.60M.
What does NERVGEN PHARMA CORP. do?
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease.